摘要
目的探讨人乳头瘤病毒(HPV-DNA)检测及血清鳞状上皮细胞抗原(SCCAg)在宫颈癌患者随访中评价预后的价值。方法对比2007年5月～2008年5月在我院复查的120例已结束治疗(手术/手术+术后放疗/全量放疗)的宫颈鳞癌患者的宫颈/阴道残端HPV-DNA及血清SCCAg阳性率。结果HPV-DNA的阳性率为49.17%,SCCAg阳性率17.50%,两者有显著差异(P<0.05),HPV-DNA灵敏度优于SCCAg。不同治疗方式患者的HPV-DNA和血清SCCAg的阳性率分别为37.50%和52.17%(手术组)、58.82%和12.50%(手术+术后放疗组)、19,50%和20.58%(放疗组),组间无明显差异(P>0.05)。结论HPV-DNA检测比血清SCCAg测定能更直接有效地评价宫颈鳞癌患者的治疗效果,两者联合可更有效地对宫颈鳞癌患者进行临床预后评价。
Objective To investigate the infection of human papilloma virus（HPV） and expression of serum squamous cell antigen （SCCAg） in the follow - up of 120 cervical squamous carcinoma patients who had received operation or operation combined with radiotherapy or only radiotherapy. Methods 120 cases of therapieal cervical squamous carcinoma patients were detected HPV - DNA by HC-Ⅱ and serum SCCAg using immunohistoehemical method. Results The positive rate of HPV - DNA and serum SCCAg was 49. 17% and 17.50% , with a significant difference between them（P 〈 0.05）. The positive rate of HPV - DNA and SCCAg in different therapical patients was 37.50% and 12.50% （operation） , 32.17% and 19.50% （ operation combined with radiotherapy） , 58.82% and 20.58% （radiotherapy） respectively. They showed an insignificant difference in the same therapicl method（P 〉 0.05）. Conclusion HPV - DNA test with HC-Ⅱ for follow - up of cervical squamous carcinoma patients was feasible. It was more sensitive than serum SCCAg. But it suggested that high risk type HPV - DNA test combined with serum SCCAg may be the independent prognostic factors.
出处
《医学研究杂志》
2009年第12期83-85,共3页
Journal of Medical Research
关键词
宫颈鳞癌
人乳头瘤病毒
SCCAG
预后
Cervical squamous carcinoma
Human papilloma virus
SCCAg
Prognosis
